Syncom Formulations Q3FY26 Standalone Profit Rises 45% to ₹18.86 Crore
Syncom Formulations reported strong Q3FY26 results. Standalone profit after tax surged to ₹18.86 crore from ₹12.79 crore year-on-year. Consolidated profit after tax increased to ₹18.91 crore from ₹13.00 crore. Revenue from operations for the quarter was ₹114.59 crore (standalone) and ₹115.44 crore (consolidated).
The financial results show a substantial year-on-year growth in profits, which is material for investors and stakeholders. However, the announcement is routine quarterly results disclosure without any major strategic announcements or significant deviations.
The company reported a significant increase in both standalone and consolidated profits for the quarter ended December 31, 2025, compared to the previous year, indicating positive financial performance.
Syncom Formulations (India) Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors approved the standalone and consolidated financial results during a meeting held on February 12, 2026.
For the quarter ended December 31, 2025, the standalone profit after tax from continuing operations stood at ₹1886.34 lakh (₹18.86 crore), marking a significant increase compared to ₹1279.12 lakh (₹12.79 crore) in the corresponding quarter of the previous year. The revenue from operations for the quarter was ₹11459.05 lakh (₹114.59 crore).
On a consolidated basis, the profit after tax from continuing operations for the quarter was ₹1890.81 lakh (₹18.91 crore), up from ₹1300.20 lakh (₹13.00 crore) in the prior year period. The consolidated revenue from operations for the quarter was ₹11544.06 lakh (₹115.44 crore).
The company also reported its results for the nine months ended December 31, 2025. Standalone profit after tax from continuing operations was ₹5143.38 lakh (₹51.43 crore), while consolidated profit after tax from continuing operations was ₹5126.36 lakh (₹51.26 crore).
The Board Meeting commenced at 3:00 PM and concluded at 4:30 PM on February 12, 2026. The financial results will be published in widely circulated English and Marathi newspapers and will be hosted on the company's website.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.